e-ISSN: 3048-9814 (Online) Vol. 2 No. 6 (2025) June 2025 Issue

Received 11 April 2025 Revised 18 May 2025 Accepted 13 June 2025



CASE REPORT

# PORT SITE TUBERCULOSIS FOLLOWING LAPAROSCOPIC CHOLECYSTECTOMY IN A NON-IMMUNOCOMPROMISED PATIENT: A DIAGNOSTIC CHALLENGE IN ENDEMIC SETTINGS

Dr Abhishek Kumar, Department of General Surgery, Katihar Medical College, Katihar

#### Abstract

*Introduction:* Port site tuberculosis (TB) following laparoscopic surgery is an uncommon but severe complication, harder to diagnose in places endemic for TB where suspicion may be delayed.

*Methods:* We herein report a case of a previously immunocompetent, 45-year-old woman, who had port site tuberculosis following an uneventful laparoscopic cholecystectomy performed upon her, three months ago.

**Results**: The patient had a slowly progressing, indurated mass at the port site of the epigastrium, along with constitutional symptoms. Histopathological examination revealed epithelioid granulomas along with caseous necrosis, and acid-fast bacilli were identified by Ziehl-Neelsen staining. The patient had a satisfactory response to conventional anti-tubercular therapy.

*Conclusion:* Port site tuberculosis should be a part of the differential diagnosis of post-laparoscopic complications of wounds, especially in areas endemic for TB. Early recognition and appropriate treatment are essential for the best possible outcomes.

Keywords: Port site tuberculosis, laparoscopic cholecystectomy, surgical site infection, endemic tuberculosis, diagnostic challenge

e-ISSN: 3048-9814 (Online) Vol. 2 No. 6 (2025) June 2025 Issue

### BACKGROUND/INTRODUCTION

Laparoscopic cholecystectomy has come to be the standard of practice for symptomatic cholelithiasis due to the minimally invasive nature and low morbidity of the procedure compared to open surgery (1). Complications, albeit rare, can occur, and among these, port site infections can occur, typically as bacterial ones during the early post-operative period (2).

RESULTS

A 45-year-old woman with no notable past medical issues came to our surgical outpatient department complaining of a slowly enlarging, painless mass at her epigastric port site. This developed over two weeks, approximately three months after she had undergone laparoscopic cholecystectomy for symptomatic gallstones.

She had previously undergone a routine laparoscopic cholecystectomy using a standard four-port technique. The surgery lasted 45 minutes and proceeded without any intraoperative complications. Her recovery was smooth, and she was discharged on the first postoperative day.

Three months after surgery, the patient reported the following:

- A firm, non-tender, 3 × 2 cm mass at the epigastric port site
- Low-grade fever around 99.5°F persisting for a week
- Night sweats and a loss of appetite

Port site tuberculosis is a rare post-laparoscopic complication, of which only a few cases are reported in the literature (3,4). Diagnosis becomes more challenging in tuberculosis-endemic countries where suspicion occurs late, leading to misdiagnosis and delayed intervention (5). The following is a case report of the diagnosis and management of port site tuberculosis after laparoscopic cholecystectomy.

- Weight loss of approximately 3 kilograms over the past month
- No respiratory complaints

## **Physical Examination**

Parameter	Finding
General appearance	Mild pallor, no acute distress
Vital signs	Temperature: 99.5°F, BP: 120/80 mmHg, HR: 88 bpm, RR: 18/min
Abdominal examination	Soft, non-tender abdomen with 3×2 cm indurated mass at epigastric port site
Lymph nodes	No palpable lymphadenopathy
Chest examination	Clear breath sounds bilaterally

# **Laboratory Investigations**

e-ISSN: 3048-9814 (Online) Vol. 2 No. 6 (2025) June 2025 Issue

**Investigation** Result Reference Range Hemoglobin 10.2 g/dL 12.0-15.0 g/dL  $8,500/\mu L$ 4.000-Total leukocyte 11,000/µL count Erythrocyte 45 mm/hr 0-20 mm/hr sedimentation rate C-reactive protein 12 mg/L <3 mg/LHIV serology Negative <10 Mantoux test 18 mm mm

Ultrasonography revealed a well-circumscribed hypoechoic lesion at the epigastric port site, measuring approximately 3.2 × 2.1 cm. The presence of internal echoes suggested an underlying inflammatory process.

induration

(negative)

Cross-sectional imaging confirmed a heterogeneously enhancing mass located in the anterior abdominal wall at the same port site, accompanied by surrounding inflammatory changes. No signs of intra-abdominal fluid collections or lymphadenopathy were observed.

The chest radiograph showed clear lung fields with no evidence suggestive of pulmonary tuberculosis.

Fine needle aspiration cytology of the lesion showed inflammatory cells along with epithelioid

granulomas, prompting an excisional biopsy for definitive diagnosis.

Histology revealed:

- Well-formed epithelioid granulomas with Langhans-type giant cells
- Central areas of caseous necrosis
- Dense chronic inflammatory infiltrates
- Ziehl-Neelsen staining confirmed the presence of acid-fast bacilli

# **Microbiological Studies**

Test	Result
Acid-fast bacilli smear	Positive (2+)
Mycobacterial culture	Mycobacterium tuberculosis complex
GeneXpert MTB/RIF	MTB detected, Rifampicin sensitivity detected

In light of both histopathological and microbiological findings, a diagnosis of port site tuberculosis was established. The patient was initiated on first-line anti-tubercular therapy (ATT) per WHO protocols:

# **Intensive Phase (2 months):**

- Isoniazid 300 mg daily
- Rifampicin 600 mg daily
- Ethambutol 800 mg daily
- Pyrazinamide 1500 mg daily

e-ISSN: 3048-9814 (Online) Vol. 2 No. 6 (2025) June 2025 Issue

**Continuation Phase (4 months):** 

- Isoniazid 300 mg daily
- Rifampicin 600 mg daily

**Clinical Course and Outcome** 

Within four weeks of initiating ATT, the patient exhibited marked clinical improvement. The

epigastric mass began to regress, and systemic symptoms such as fatigue and low-grade fever resolved. At the 6-month follow-up, the lesion had completely resolved, with no clinical signs of recurrence.

#### **DISCUSSION**

Tuberculosis (TB) of the port site following laparoscopic surgery is an exceptionally rare postoperative complication, with only isolated cases reported worldwide. This condition poses a diagnostic and clinical challenge due to its atypical presentation and delayed onset. The presumed pathogenesis involves hematogenous dissemination of Mycobacterium tuberculosis to the site of surgical trauma. This seeding may be facilitated by local tissue injury and inflammatory responses induced during the laparoscopic procedure. Although the patient may appear immunocompetent, subtle or undetected immunosuppression could contribute susceptibility. Furthermore, in regions with a high endemic burden of TB, the likelihood of latent infection reactivation is significantly elevated, increasing the risk of such rare manifestations.

Several factors may predispose individuals to this unusual complication. These include residing in or originating from TB-endemic areas, surgical manipulation leading to localized immune disruption,

and the inherently indolent course of tuberculosis, which may delay clinical suspicion and diagnosis. Despite the overall good health of most affected individuals, undiagnosed or latent TB infections can manifest under specific post-surgical conditions.

Diagnosing port site TB is often challenging due to its non-specific and insidious clinical progression. It may present as a persistent or non-healing surgical wound, occasionally mimicking pyogenic infections or malignancies. The lack of acute systemic symptoms and the slow evolution of the lesion often lead to misdiagnosis or delayed recognition. Clinicians must consider port site TB in the differential diagnosis of chronic, non-resolving surgical site lesions, especially in TB-endemic regions.

Differential diagnoses include bacterial infections, which typically have an acute onset with purulent discharge and fever and respond well to conventional antibiotics. Malignancy may present with progressive

e-ISSN: 3048-9814 (Online) Vol. 2 No. 6 (2025)

June 2025 Issue

lesion growth and firm consistency, necessitating

histopathological and immunohistochemical

evaluation. Foreign body reactions, often associated

with retained suture material or mesh, can cause

granulomatous inflammation visible under polarized

light microscopy. Actinomycosis, another chronic

infection, may manifest with draining sinuses and the

presence of sulfur granules, distinguishable via

histology and culture.

Management of port site tuberculosis relies heavily

on timely recognition and prompt initiation of anti-

tubercular therapy (ATT). Most patients respond

favorably to pharmacological treatment alone, but

surgical excision may be necessary for large,

persistent, or non-healing lesions. Close clinical

monitoring is essential to evaluate treatment

response and identify potential adverse effects of

anti-TB medications. Additionally, public health

measures, including screening of close contacts, are

recommended to prevent further transmission,

especially in household or occupational settings.

The prognosis of port site TB is generally favorable

when appropriate therapy is administered.

Recurrence is rare if the patient completes the full

course of ATT. Early diagnosis and a high index of

suspicion in atypical postoperative wound

presentations are key to preventing complications

and ensuring successful outcomes.

CONCLUSION

This case underscores a rare but important

diagnosis—port site tuberculosis. Particularly in

regions where TB is endemic, clinicians should

maintain a high index of suspicion when faced with

unexplained postoperative masses. Early diagnosis

and guideline-based treatment offer excellent

outcomes, emphasizing the need for continued

vigilance among surgeons and healthcare providers.

LIMITATION

This report is limited by its single-case design, which

restricts broader applicability of the findings.

**RECOMMENDATION** 

Clinicians in TB-endemic regions should maintain a

high index of suspicion for port site TB in patients

presenting with delayed post-laparoscopic wound

complications.

**ACKNOWLEDGEMENT** 

The author thanks the Department of General

Surgery at Katihar Medical College for clinical

support and case management.

**CONFLICT OF INTEREST** 

The author declares no conflict of interest related to

this study.

LIST OF ABBREVIATIONS

TB – Tuberculosis; ATT – Anti-Tubercular Therapy

FNAC – Fine Needle Aspiration Cytology

CT – Computed Tomography

HIV - Human Immunodeficiency Virus.

e-ISSN: 3048-9814 (Online) Vol. 2 No. 6 (2025) June 2025 Issue

### REFERENCES

- Coccolini F, Catena F, Pisano M, et al. Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and metaanalysis. Int J Surg. 2015;18:196-204. doi:10.1016/j.ijsu.2015.04.083
- Bisgaard T, Klarskov B, Trap R, et al. Microbiological analysis of infected laparoscopic ports. Surg Endosc. 2003;17(8):1177-1180. doi:10.1007/s00464-002-9126-4
- 3. Sharma D, Sharma R, Sharma A. Port site tuberculosis following laparoscopic cholecystectomy: a case report. J Min Access Surg. 2010;6(3):76-78. doi:10.4103/0972-9941.68583
- Kapoor VK, Chattopadhyay TK. Port site tuberculosis: a rare complication of laparoscopic surgery. Surg Laparosc Endosc Percutan Tech. 2004;14(1):43-44. doi:10.1097/00129689-200402000-00011
- World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Available from: https://www.who.int/publications/i/item/97 89240083851
- Gupta R, Singal R, Sharda VK, et al. Port site tuberculosis following laparoscopic cholecystectomy. J Minim Access Surg.

- 2011;7(4):260-262. doi:10.4103/0972-9941.85646
- 7. Basu S, Shukla VK. Port site tuberculosis following laparoscopic cholecystectomy. Surg Laparosc Endosc Percutan Tech. 2007;17(2):130-132. doi:10.1097/SLE.0b013e31803b5d9c
- Nahman BJ, Cunningham JD, Yao D, et al. Mycobacterium tuberculosis at laparoscopic port sites. Surg Endosc. 2001;15(6):636. doi:10.1007/s004640000374
- 9. Chakrabarti S, Garg PK, Dutta A, et al. Port site tuberculosis following laparoscopic cholecystectomy: report of two cases. J Laparoendosc Adv Surg Tech A. 2005;15(6):614-616. doi:10.1089/lap.2005.15.614
- 10. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Available https://www.who.int/publications/i/item/97 89240007048
- 11.
- 12.